Profound Medical and Telix Pharmaceuticals Enter Co-Education Agreement to Advance PSMA-Informed Prostate Care
Profound Medical and Telix Pharmaceuticals announced a co-education agreement to promote PSMA-PET molecular imaging and Profound’s MRI-guided TULSA-PRO platform. The collaboration sets out joint educational initiatives and describes planned software integration work to incorporate PSMA-PET data into Profound’s Treatment Delivery Console.